Physician profile
Manish Gera
NPI 1497729818
$112,828.39
in general payments reported to CMS, 2019-2025
36 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $14K · 2021: $7,068 · 2022: $13K · 2023: $16K · 2024: $18K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $7,069 · Travel and Lodging: $4,212 · Consulting Fee: $1,688 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $24,818.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,506.25 |
| Food and Beverage | $7,068.52 |
| Travel and Lodging | $4,211.63 |
| Consulting Fee | $1,688.00 |
| Education | $164.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $40,316.87 | 2019-2025 | Lokelma, Farxiga |
| Calliditas Therapeutics US INC. | $30,599.66 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $15,941.67 | 2019-2025 | Veltassa, Korsuva |
| Mallinckrodt Enterprises LLC | $12,927.12 | 2019 | |
| Mallinckrodt Hospital Products INC. | $4,944.94 | 2020-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $2,241.72 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $966.05 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Novartis Pharmaceuticals Corporation | $541.09 | 2019-2025 | |
| Amgen INC. | $525.34 | 2019-2025 | Krystexxa, Tavneos |
| Astellas Pharma US INC | $407.73 | 2019-2021 | |
| Novo Nordisk INC | $342.93 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Travere Therapeutics, INC. | $334.69 | 2023-2025 | Filspari |
| Horizon Therapeutics Plc | $311.64 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $296.11 | 2019-2025 | Jynarque, Voyxact |
| Opko Pharmaceuticals, LLC | $281.29 | 2019-2025 | Rayaldee |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $266.89 | 2023-2025 | Gemtesa |
| Aurinia Pharma U.S., INC. | $199.67 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.16 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $187.78 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $104.35 | 2022-2024 | Benlysta, Jesduvroq |
| Lilly USA, LLC | $103.24 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $85.32 | 2020-2022 | |
| Lundbeck LLC | $81.83 | 2019-2020 | |
| Urovant Sciences INC | $80.13 | 2022 | |
| Daiichi Sankyo INC. | $72.68 | 2019-2021 | |
| Shire North American Group INC | $67.81 | 2019 | |
| Ani Pharmaceuticals, INC. | $58.37 | 2023-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $56.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.79 | 2022-2023 | Gattex |
| Baxter Healthcare | $48.33 | 2024 | Renal - Acute |
| Janssen Pharmaceuticals, INC | $46.10 | 2019 | |
| Shield Therapeutics INC | $46.06 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $34.00 | 2021-2023 | |
| Apellis Pharmaceuticals, INC. | $26.87 | 2025 | |
| Arbor Pharmaceuticals, INC. | $17.77 | 2019 | |
| Pfizer INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Gera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.